References

1. Kurnit KC, et al. Obstet Gynecol.2021;137(1):108–121. Family history as a risk assessment tool. Committee Opinion No. 478. American College of Obstetricians and Gynecologists. Obstet Gynecol 2011;117:747–50. [PubMed] [Obstetrics & Gynecology]
2. Hereditary cancer syndromes and risk assessment. Committee Opinion No. 634. American College of Obstetricians and Gynecologists. Obstet Gynecol 2015;125:1538–43. [PubMed] [Obstetrics & Gynecology]
3. Prior TW. Carrier screening for spinal muscular atrophy. Professional Practice and Guidelines Committee. Genet Med 2008;10:840–2. [PubMed] [Full Text]
4. Prior TW, Snyder PJ, Rink BD, Pearl DK, Pyatt RE, Mihal DC, et al. Newborn and carrier screening for spinal muscular atrophy. Am J Med Genet A 2010;152A:1608–16.[PubMed]
5. Mailman MD, Heinz JW, Papp AC, Snyder PJ, Sedra MS, Wirth B, et al. Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet Med 2002;4:20–6. [PubMed] [Full Text]
6. Watson MS, Cutting GR, Desnick RJ, Driscoll DA, Klinger K, Mennuti M, et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel [published errata appear in Genet Med 2005;7:286; Genet Med 2004;6:548]. Genet Med 2004;6:387–91. [PubMed] [Full Text]
7. Cystic Fibrosis Foundation. 2015 patient registry annual data report . Bethesda (MD): CFF; 2016. Available at: https://www.cff.org/Our-Research/CF-Patient-Registry/2015-Patient-Registry-Annual-Data-Report.pdf. Retrieved February 6, 2017.
8. American College of Medical Genetics and Genomics. Technical standards and guidelines for CFTR mutation testing. American College of Medical Genetics Standards and Guidelines for Clinical Genetics Laboratories . Bethesda (MD): ACMG; 2011. Available at: http://www.acmg.net/docs/CFTR_Mutation_Testing_2011.pdf. Retrieved September 12, 2016.
9. Cystic Fibrosis Centre, Hospital for Sick Children. Cystic fibrosis mutation database . Available at: http://www.genet.sickkids.on.ca/CFTR/app. Retrieved September 12, 2016.
10. Watson MS, Cutting GR, Desnick RJ, Driscoll DA, Klinger K, Mennuti M, et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. Genet Med 2004;6:387–91. [PubMed] [Full Text]
11. Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med 2010;38:S512–21. [PubMed] [Full Text]
12. Davies SC, Cronin E, Gill M, Greengross P, Hickman M, Normand C. Screening for sickle cell disease and thalassaemia: a systematic review with supplementary research. Health Technol Assess 2000;4:i-v, 1–99. [PubMed]
13. Duffy TP. Hematologic aspects of pregnancy. In: Burrow GN, Duffy TP, Copel JA, editors. Medical complications during pregnancy . Philadelphia (PA): Elsevier Saunders; 2004. p. 69–86.
14. Kazazian HHJr. The thalassemia syndromes: molecular basis and prenatal diagnosis in 1990. Semin Hematol 1990;27:209–28. [PubMed]
15. Serjeant GR, Serjeant BE. Sickle cell disease . 3rd ed.New York (NY): Oxford University Press; 2001.
16. Hatton DD, Sideris J, Skinner M, Mankowski J, Bailey DB Jr, Roberts J, et al. Autistic behavior in children with fragile X syndrome: prevalence, stability, and the impact of FMRP. Am J Med Genet A 2006;140A:1804–13. [PubMed]
17. Kronquist KE, Sherman SL, Spector EB. Clinical significance of tri-nucleotide repeats in Fragile X testing: a clarification of American College of Medical Genetics guidelines. Genet Med 2008;10:845–7. [PubMed] [Full Text]
18. Monaghan KG, Lyon E, Spector EB. ACMG Standards and Guidelines for fragile X testing: a revision to the disease-specific supplements to the Standards and Guidelines for Clinical Genetics Laboratories of the American College of Medical Genetics and Genomics. Genet Med 2013; 15:575–86. [PubMed] [Full Text]
19. Pesso R, Berkenstadt M, Cuckle H, Gak E, Peleg L, Frydman M, et al. Screening for fragile X syndrome in women of reproductive age. Prenat Diagn 2000;20:611–4. [PubMed]
20. Cronister A, Teicher J, Rohlfs EM, Donnenfeld A, Hallam S. Prevalence and instability of fragile X alleles: implications for offering fragile X prenatal diagnosis. Obstet Gynecol 2008;111:596–601. [PubMed] [Obstetrics & Gynecology]
21. Willemsen R, Bontekoe CJ, Severijnen LA, Oostra BA. Timing of the absence of FMR1 expression in full mutation chorionic villi. Hum Genet 2002;110:601–5. [PubMed]
22. Dong J, Edelmann L, Bajwa AM, Kornreich R, Desnick RJ. Familial dysautonomia: detection of the IKBKAP IVS20(+6T --> C) and R696P mutations and frequencies among Ashkenazi Jews. Am J Med Genet 2002;110:253–7. [PubMed]
23. Fanconi Anemia Research Fund. Fanconi anemia: guidelines for diagnosis and management . 4th ed.Eugene (OR): FARF; 2014. Available at:http://fanconi.org/images/uploads/other/FA_Guidelines_4th_Edition_Revised_Names_in_Appendix.pdf. Retrieved September 12, 2016.
24. Hoffman JD, Greger V, Strovel ET, Blitzer MG, Umbarger MA, Kennedy C, et al. Next-generation DNA sequencing of HEXA: a step in the right direction for carrier screening. Mol Genet Genomic Med 2013;1:260–8. [PubMed] [Full Text]
25. vanBael M, Natowicz MR, Tomczak J, Grebner EE, Prence EM. Heterozygosity for Tay–Sachs disease in non-Jewish Americans with ancestry from Ireland or Great Britain. J Med Genet 1996;33:829–32. [PubMed] [Full Text]
26. Schneider A, Nakagawa S, Keep R, Dorsainville D, Charrow J, Aleck K, et al. Population-based Tay–Sachs screening among Ashkenazi Jewish young adults in the 21st century: Hexosaminidase A enzyme assay is essential for accurate testing. Am J Med Genet A 2009;149A:2444–7